

VOLUME 35 1990

SUBJECT INDEX

- ACTH, 739
 ACTH analog, 99
 Acetylcholine, 143, 523
 Acquisition, 553
 Activity, 511
 Activity monitor (wheel-shaped), 1003
 Adenosine, 85, 791
 Adrenalectomy, 171, 739, 753
 Adrenoceptors, 41
 Adrenocorticotropin, 99
 Adrenoreceptors, 21
 Afterdischarges, 815
 Aggression, 699
 Aggressive behavior, 357
 Aging, 589, 747
 Alcohol, 357, 693
 Alcohol-barbiturate combination, 443
 Alcohol drinking, 465
 Alcohol sensitivity, 437, 721
 Allantoxanamide, 791
 Alprazolam, 651
 Alprazolam brain levels, 651
 Alprazolam dependence, 643
 Alprazolam plasma levels, 651
 Alzet minipumps, 219
 Amantadine, 29, 291
 Amino acid analog, 911
 Amino acids, 127, 133, 195
 Amnesia, 747
 Amphetamine, 55, 89, 121, 219, 301, 461, 517, 595, 871, 989
d-Amphetamine, 457, 631, 759
 (+)-Amphetamine, 971
 Amygdala, 815
 Analgesia, 137, 157, 225, 567, 731
 Analgesic drugs, 567
 Androgens, 307
 Anhedonia, 273
 Anorectic drugs, 301
 Anorexia, 51, 61, 457, 461
 Anorexia nervosa, 885
 Anticonvulsant drugs, 537
 Anticonvulsants, 815
 Antineoplastic, 767
 Antipanic, 451
 Antipsychotic effect, 937
 Anxiety, 451, 775, 923
 Anxiety model, 713
 Anxiogenesis, 263
 Anxiolysis, 85, 263
 Anxiolytic effect, 503
 Anxiolytic profile, 607
 Anxiolytics, 121
 Apomorphine, 117, 201, 391, 511, 583, 659, 753, 937, 989
 Apomorphine-induced climbing, 93
 Appetite, 61, 865
 Area postrema, 543
 Ascorbate, 55
 Ascorbic acid, 871
 D-Aspartic acid, 47
 Ataxia, 815
 Atria, 99
 Attenuation of abstinence syndrome, 47
 Autoimmunity, 747
 Autonomic nervous system, 21
 Autoreceptor, 201
 Aversion learning, 543
 Avoidance behavior, 685
 Avoidance learning, 747

 BC-105, 61
 BMJ 21502, 553
 BW A78C, 85
 Barbiturate, 317, 889
 Behavior, 117, 631, 713, 847, 911
 Behavioral, 7
 Behavioral history, 405
 Behavioral measures of anxiety, 121
 Behavioral tolerance, 273, 561
 Behavioral toxicology, 583
 Benzodiazepine inverse agonist, 889
 Benzodiazepine receptor antagonist, 747
 Benzodiazepine receptors, 503
 Benzodiazepines, 121, 281, 373, 379, 841
 Beta-adrenoceptors, 335
 Beta carboline carboxylic acid ethyl ester (BCCE), 713
 Binding sites, 99
 Biogenic amines, 989
 Blood acetaldehyde, 437
 Body temperature, 511
 Body weight, 219, 301
 Brain, 465, 511, 995
 Brain cortex, 255
 Brain development, 943
 Brain evoked potential, 341
 Brain injury, 497
 Bright light, 523
 Buspirone, 117, 781

 C57BL/6J, 311
 C57BL/6NNia mice, 747
 CCK-8, 493
 CPP, 785
 mCPP, 181
 CY 208-243, 105
 Caerulein, 143, 855
 Caffeine, 477, 631, 791
 Calcium channel antagonists, 557
 Calcium channel inhibitors, 601
 Calcium channels, 833
 Caloric intake, 301
 Carbamazepine, 897
 Carbohydrates, 665, 923
 Carbon monoxide, 341
 Cardiovascular changes, 437
 Catalepsy, 753
 Catecholamines, 165
 Catecholestrogens, 307
 Caudate, 871
 Cerebellum, 693
 Cerebral ventricle, 465
 Chickens, 567
 Chlordiazepoxide, 363, 373, 451, 897
 Chlordiazepoxide metabolism, 363
 p-Chloroamphetamine, 995
 N-[4-(2-Chloromethylamino)]-2-pyrrolidone (BM 123), 511
 p-Chlorophenylalanine, 847
 Chlorophenylpiperazine, 181
 Chlorpromazine, 29, 897
 Choice, 413
 Choice test, 15
 Cholecystokinin, 51
 Cholecystokinin-octapeptide, 143, 493
 Choline, 143
 Choline acetyltransferase (ChAT), 589
 Cholinergic, 523
 Cholinergic receptors, 171
 Cholinergic system, 903
 Cholinesterase, 561
 Chronic, 291
 Chronic administration, 477, 933
 Chronic benzodiazepine, 419
 Chronic diet treatment, 363
 Chronic drug treatment, 489
 Chronic ethanol consumption, 75
 Chronic intrathecal injection, 807
 Chronic treatment, 481
 Chronic variable stress, 335
 Cingulate cortex, 871
 Circadian rhythms, 35, 923
 Circling behavior, 877
 Classical conditioning, 583
 Clonazepam, 815, 933
 Clonidine, 35
 Cocaine, 121, 187, 237, 245, 269, 595, 17, 631, 743, 949
 Cocaine analogs, 949
 [³H] Cocaine binding, 949
 Cocaine preference, 187
 Cocaine self-administration, 245
 Codeine, 413, 567
 Cognition, 955
 Cognitive decline, 747
 Concurrent schedules, 443
 Conditioned drug effects, 367
 Conditioned place aversion, 89
 Conditioned place preference, 89, 485
 Conditioned taste aversion, 583, 803
 Conditioned taste avoidance, 583
 Conditioning, 373
 Conflict behavior, 451
 Conflict test, 413
 Consolidation, 127, 133
 Convulsions, 85
 Convulsive crises, 713
 Cortex, 589
 Cortical choline acetyltransferase, 151
 Corticosterone, 739
 Corticostriatal pathway, 55
 Cotreatment, 291
 Counter-irritation, 731
 Cricket, 127, 133
 Cross tolerance, 637, 807
 Cumulative dosing, 537
 Cytisine, 735

 D-1 receptors, 285
 D1 and D2 DA receptor interactions, 877
 D-1 and D-2 receptors, 105
 D-2 receptors, 285
 D₂ receptors, 117
 DA receptors, 937

DBA/2J, 311
 DFP, 561
 DMBA, 767
 l-DOPA, 465
 DOPAC, 195
 DRL, 595
 Defense, 775
 Defensive burying, 451
 Delayed nonmatching to position procedure, 903
 Delta, kappa and mu opioid receptors, 69
 2-Deoxyglucose, 865
 Dependence, 137
 Dependence, oxazepam, 347
 Desipramine, 451
 Development, 693
 Dextromethorphan, 829
 Diabetes, 473, 577
 Diazepam, 121, 263, 405, 419, 775, 933
 Diazepam withdrawal, 419
 Diet, 225, 911
 Diet selection, 665
 α -Difluoromethylornithine, 255
 Dihydropyridine binding sites, 833
 [125 I]-2-(2,5-Dimethoxy-4-iodophenyl)aminoethane, 211
 Discrete brain, 143
 Discrimination, 517
 Discriminative stimulus, 351
 Domestic fowl, 567
 Dopa-decarboxylase inhibition, 465
 Dopamine, 105, 111, 117, 195, 201, 285, 291, 327, 465, 497, 577, 643, 659, 685, 735, 743, 937, 995
 Dopamine and 5-HT receptor antagonist, 607
 Dopamine antagonist, 351
 Dopamine receptors, 93, 511
 Dorsal immobility response, 307
 Dose response, 861
 Dosing schedule, 273
 Drinking, 69
 Drug abuse, 517, 743
 Drug-admixed food, 413
 Drug cumulation, 273
 Drug discrimination, 117, 405, 527, 537, 781, 797, 949, 971
 Drug interactions, 443
 Drug reinforcement, 443
 Drug reward, 485
 Drug seeking behavior, 413
 Drug self-administration, 311
 Duration of action, 861
 Dynorphin, 429, 643

 E.A.A. antagonists, 999
 EEG, 933
 Elation, 923
 Elevated plus-maze, 721
 Endogenous opioids, 69
 β -Endorphin, 807
 Energy restriction, 677
 Epilepsy, 815
 Epileptiform activity, 999
 Estradiol, 307
 Estrogen, 767
 Ethanol, 259, 363, 465, 485, 775, 803
 Ethanol/alcohol, 443
 Ethanol-chlordiazepoxide cross-dependence, 379
 Ethanol intake, 379, 493
 Ethanol metabolism, 363
 Ethanol self-administration, 259

 Ethanol sensitivity, 469
 N-Ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), 877
 Experience-induced plasticity, 255
 Exploration, 201, 317, 557
 Exploratory activity, 121, 503, 855

 FG7142, 889
 Facial flushing, 437
 Fasting, 391
 Fat, 665, 671
 Feed efficiency, 301
 Feeding, 225
 Fenfluramine, 527, 971
 Fetal alcohol syndrome, 693
 Fetus, 943
 Fixed-ratio schedules, 443
 Flesinoxan, 781
 Flumazenil, 347, 503, 747, 889
 Flumazenil plasma levels, 651
 Flumazenil precipitated abstinence in dogs, 651
 Fluoxetine, 51, 237, 259
 Fluprazine hydrochloride, 699
 Food choice, 911
 Food deprivation, 865
 Food intake, 61, 461, 493, 865, 911
 Food-reinforced behavior, 481
 Forced swimming test, 557
 Free fatty acids, 677
 Free rhesus monkeys, 713
 Freezing behavior, 685

 GR38032F, 955
 Genetic, 15
 Genetic selection for differences in ethanol preference, 385
 Glucose, 677
 Glutamate, 815
 Glycolipid, 75
 Glycosyltransferase, 75
 Growth, 911
 Guinea pig ileum-myenteric plexus, 705
 Gulls, 7

 5-HT, 61, 157
 5-HT₁ sites, 335
 5-HT_{1A}, 781
 5-HT_{1A} agonists, 251
 5-HT_{1A} receptors, 251
 5-HT_{1B} stimulation, 841
 5-HT₂ receptor, 211, 251
 5HT₃ receptor, 955
 HVA, 195
 Habituation, 151
 Hallucinogens, 211
 Haloperidol, 111, 273, 291, 391, 457, 481, 753, 855, 897
 Halothane, 889
 Head-shake response, 151
 Hedonics, 671
 Heroin, 351
 Herpes simplex virus-type 1, 617
 γ -Hexachlorocyclohexane, 1003
 Hibernation, 705
 Hibernation-induction trigger (HIT), 705
 High-carbohydrate diet, 301
 High-fat diet, 301
 Hippocampal slices, 999
 Hippocampal sympathetic ingrowth, 21
 Hippocampus, 589, 785, 847, 871
 Humans, 157, 397

 Humoral immunity, 617
 Hunger, 923
 3-Hydroxybenzylhydrazine dihydrochloride, 465
 5-Hydroxytryptamine, 943
 Hyperalgesia, 567
 Hyperphagia, 373, 865
 Hypersensitivity, 291
 Hypoalgesia, 567
 Hypophysectomy, 739

 ([125 I]-2C-I), 211
 Imipramine, 335, 451
 Inbred mice, 121
 Indomethacin, 601
 Ingestion, 15
 Ingestive behaviors, 583
 Inhibition, 231
 Inhibitors, 561
 Insulin, 865
 Intense grooming, 105
 Intensification of abstinence syndrome, 47
 Intensity, 671
 Intracerebroventricular, 69
 Intramuscular dosing, 797
 Intrathecal, 1
 Intravenous, 237
 In vivo, 55
 Irreversible muscarinic agonist, 511
 Isolated mice, 841

 Kainic acid, 1
 Ketamine, 829
 Ketanserin, 181
 Kindling, 815
 Kinetics of response, 797
 Kinins, 437
 Kynurenic acid, 815

 LH releasing hormone, 577
 LY 171555, 877
 Large neutral amino acids, 911
 Lead, 7
 Learning, 21, 127, 133, 631
 Learning and memory, 981
 Leucine, 911
 Level of arousal, 269
 Light/dark choice procedure, 85
 Lindane, 1003
 13-Lined ground squirrel (*Citellus tridecemlineatus*), 705
 Lithium, 291, 897
 Locomotion, 85, 735
 Locomotor activity, 35, 231, 481, 617, 791, 897
 Long-sleep and short-sleep mice, 469
 Long-term potentiation, 533, 785
 Long-term treatment, 855

 MDA, 971
 MDMA, 971
 MK-212, 181
 MK-329 (L-364,718), 51
 MK-801, 533, 785, 815
 MR2266, 69
 Maharishi-4, 767
 Male rat, 327
 Male rat sexual behavior, 263
 Male sex behavior, 659
 Mammary tumors, 767
 Mania, 897
 Massed extinction, 41

- Meal size, 923
Medial septal lesions, 21
Memory, 21, 127, 133, 553, 747, 903
Meprobamate, 405
3-Mercaptopropionic acid, 721
Mesencephalon, 989
Mesolimbic-mesocortical DA system, 937
Metabolism, 291
Methamphetamine, 391, 637, 897
4-Methylaminorex, 517
N-Methyl-D-aspartate, 785
Methyl β -carboline-3-carboxylate, 281
16-Methyl cyprenorphine, 69
Methylenedioxyamphetamine, 637
Methylenedioxymethamphetamine, 637
Methylphenidate, 121
 α -Methyl-dl-p-tyrosine, 201
Methysergide, 181
Metoclopramide, 285, 685
Mianserin, 181
Mice, 85, 231, 285, 357
Microanalysis of behavior, 1003
Microcomputer, 1003
Microdialysis, 201
Milk-drinking, 637
Miniature endplate potentials, 321
Monkeys, 553, 759, 949
Monoacetylmorphine, 351
Monoamine, 391
Monoamine-related substrates, 231
Mood states, 861
Morphine, 15, 137, 157, 225, 231, 311, 351, 367, 413, 567, 595, 643, 665, 807
Morphine dependence, 47
Motivation, 219
Motor activity, 317
Motor behavior, 285
Motor impairments, 273
Motor performance, 419
Mouse, 143, 281, 317, 391
Mouse strains, 29
Multidimensional scaling, 397
Multiple-trial learning, 281
Muscarinic receptors, 511, 589
- NMDA, 815
NMDA receptor, 533
NSD-1015, 465
NZB/BINJ mice, 747
Naloxone, 385, 567, 665, 705
Naltrexone, 1
Narcotic antagonists, 567
Narcotic drugs, 567
Negative alliesthesia, 885
Neocortex, 847
Neonate, 571
Neostriatum, 55, 989
Neurofilament, 693
Neuroleptic agent, 607
Neuroleptic drugs, 685
Neuroleptics, 111
Neuromuscular transmission, 321
Neuronal uptake, 99
Neurotoxicity, 995
Neurotransmitter, 195
Nicotine, 171, 341, 489, 523, 671, 735
Nociception, 225, 473
Nonbenzodiazepine tranquilizing drugs, 841
Nonreward, 41
Nonsmokers, 671
Nootropic, 553
Noradrenaline, 41, 327
- Nor-binaltorphimine, 69
d-Norephedrine, 865
d,l-Norephedrine, 865
l-Norephedrine, 457, 865
Norepinephrine, 497, 577
Norepinephrine turnover, 677
Norfenfluramine, 527
Norleucine, 911
Nucleus accumbens, 871
Nucleus basalis magnocellularis lesions, 151
- 8-OH-DPAT, 781
ORG 5222, 607
Odor, 775
Odor detection, 699
Olfaction, 699
Olfactory associations, 617
Olfactory threshold, 699
Ondansetron, 955
Open-field activity, 165
Operant behavior, 181
Operant responding, 111
Operant test battery, 759
Opiate, 219, 397, 567
Opiate-induced feeding, 665
Opiate system, 885
Opioid, 1, 385, 397, 567, 705
Opioid antagonists, 69
Opioid peptides, 767
Opioid physical dependence, 311
Opioid receptors, 1
Oral administration, 861
Oral route, 245, 443
Organochlorine insecticides, 1003
Organophosphates, 321
Oxazepam, 347
Oxytocin, 601
- PCP, 93
PCP receptors, 1
PK 11195, 933
PLG, 47
Pain, 225, 341, 567, 731
Palatability, 583
Panic disorder, 451
Pantethine, 165
Papaverine, 29
Parachlorophenylalanine, 731
Pargyline, 451
Passive avoidance, 727
Penicillin, 999
Penile erection, 601, 659
Pentobarbital, 405, 443, 889
Performance, 269
Pergolide, 201
Perifornical hypothalamus, 461
Pertussis toxin, 137
Pharmacokinetics, 797
Phencyclidine, 93, 533, 797
Phentolamine, 21
Phenylpropanolamine, 457, 461, 865
Phenytoin, 537
Phospholipidic effectors, 75
Physical dependence, 15
Pigeons, 537, 631, 797, 971
Pilocarpine, 871
Pirenzepine, 589
Pituitary adrenal, 739
Pizotifen, 61
Plasma membrane, 75
Polar bear (*Ursus maritimus*), 705
Polydrug abuse, 443
- Postnatal, 7
Postoperative pain, 157
Precipitated abstinence, 829
Predator, 775
Preference, 15, 413
Prefrontal cortex, 743
Prenatal exposure, 617
Primates, 659
Progesterone receptors, 767
Prolactin, 767
Propranolol, 21, 41
Prostaglandins, 601
Protein, 665
Pseudocatalepsy, 753
Psychopharmacology, 397
Purkinje cell, 693
Putrescine, 255
- [³H] QNB binding, 511
Quinuclidinyl benzilate (QNB), 589
Quipazine, 181
Quipazine-induced head shake response, 251
- RO15-1788, 263, 379, 503, 651
RO15-4513, 803, 889
Ro 5-4864, 933
Radial arm maze, 533, 785
Radial maze, 429
Radioligand binding, 855
Rat, 15, 35, 41, 61, 89, 93, 151, 165, 195, 219, 237, 255, 259, 269, 273, 405, 413, 429, 481, 511, 527, 543, 557, 595, 601, 637, 699, 739, 781, 933, 995, 999, 1003
Receptor, 291
 ω_3 Receptor, 933
Receptor binding, 211
Recovery of function, 497
Reflex development, 617
Reinforcement, 89, 259, 595
Reinforcement density hypothesis, 273
Reinforcing effect, 413
Relative reinforcing effects, 443
Repeated acquisition, 631
Repeated administrations, 111
Repeated measures, 753
Repeated treatment, 557
Reserpine, 201
Responses to mirrors, 121
Restrained rhesus monkeys, 713
Retention, 151
Rhesus monkeys, 117, 245, 443, 659
Righting reflex, 889
Risk assessment, 775
- SCH 23390, 111, 285, 877
SKF 38393, 877
Saccharin/glucose, 69
Saccharin intake, 219
Satiety peptide, 493
Schedule-induced wheelrunning, 739
Schedule induction, 187
Scopolamine, 291, 847
Scopolamine methyl nitrate, 543
Scratching, 1
Sedation, 85
Seizure susceptibility, 721
Seizures, 815
Selected rat lines, 721
Self-administration, 187, 237
Self-stimulation, 743
Senescence-accelerated mice, 727
Sensitivity, 671

Sensitization, 273
 Sensorimotor cortex, 497
 Septum, 989
 Serotonin, 51, 61, 237, 465, 571, 995
 Serotonin agonists, 181
 Serotonin depletion, 731
 Serum cocaine, 187
 Serum drug levels, 617
 Sex behavior, 577
 Sex differences, 903
 Sexual arousal, 367
 Sexual behavior, 327, 571, 643
 Sexual behavior in male rats, 367
 Sexual differentiation, 357
 Sigma receptors, 1
 Signal detection, 699
 Skills performance, 861
 Smokers, 671
 Smoking, 341
 Social facilitation, 923
 Social isolation, 469
 Sodium appetite, 823
 Soman, 561
 Somatostatin, 165
 Spatial memory, 429, 785
 Specific appetite, 489
 Spermidine, 255
 Spermine, 255
 Spinal cord, 473
 Spontaneous behavior, 981, 1003
 Squirrel monkeys, 181
 Staircase test, 85
 Stereotypic behavior, 291
 Stereotypy, 511
 Stimulants, 517
 Stimulation, 231
 Strain differences, 171
 Stress, 41, 943
 Stress-induced ACTH corticosterone and prolactin responses, 963
 Striatum, 231, 307, 511, 589
 Strychnine, 833
 Subchronic administration, 477
 Subjective effects, 397
 Subjective response, 341
 Substance P, 473
 Sucrose, 225, 489
 Sufentanil, 219
 Sulpiride, 285
 Suppression of abstinence syndrome, 829
 Sweet, 671
 TFMPP, 181
 TRH, 727
 Tachykinins, 823
 Tail-flick, 225
 Taste aversion, 219
 Taste reactivity test, 583
 Telemetry, 523
 Tertiary and quaternary naltrexone, 963
 Testicular enzymes, 29
 Testosterone, 357, 577
 Δ^9 -Tetrahydrocannabinol, 861
 Thermal nociception, 567
 Thermoregulation, 523
 Thioridazine, 291, 937
 Thirst, 823, 923
 Time-course, 527
 Tolerance, 317, 321, 373, 637, 807
 Trazodone, 181
 Triazolam, 405
 Trifluoromethylphenylpiperazine, 181
 Tryptophan, 157, 943
 Turning, 989
 Tyrosine, 195
 Uric acid, 791, 871
 Vagotomy, 143
 Vasopressin, 981
 Ventral tegmental area, 643, 735
 Ventromedial thalamic nucleus, 55
 Vertical and horizontal locomotion, 391
 Vibrissae, 989
 Vigilance, 269
 Volatile anesthesia, 889
 Voltammetry, 55, 871
 Voluntary ethanol consumption, 385
 Water intake, 111
 Water maze, 429
 Weight pulling method, 413
 Wheelrunning, 477
 Withdrawal, 219, 317
 Withdrawal signs, 379
 Working memory, 533
 YM-14673, 727
 Yawning, 201, 601
 Zk 39106, 263
 Zopiclone, 405

AUTHOR INDEX

Abbott, F. V., 157
 Abe, E., 391
 Abia, K. A., 121
 Abou-Issa, H., 767
 Abraham, W. C., 785
 Ågmo, A., 327
 Agüero, A., 543
 Allikmets, L., 855
 Alling, C., 165
 Alliot, J., 981
 Amato, G., 937
 Amdur, R. L., 291
 Amstrup, S. C., 705
 Andre, E., 713
 Anton, G., 713
 Apfelbaum, M., 885
 Aragort, W., 133
 Argiolas, A., 601
 Aricioglu, F., 47, 829
 Arnedo, M., 543
 Asencio, M., 237
 Ashe, W. K., 617
 Ator, N. A., 405
 Aubin, H. J., 713
 Axt, K. J., 995
 Baker, G. B., 847
 Baklien, A., 127
 Banks, A. N., 93
 Barber, D. J., 51
 Barnes, J. M., 955
 Barrera, C. M., 791
 Basse-Tomusk, A., 55
 Bassett, J. R., 99
 Basso, A. M., 335
 Beardslee, S. L., 451
 Belknap, J. K., 311
 Bernabei, A. A., 589
 Biggio, G., 877
 Bird, K. D., 861
 Blackburn, J. R., 685
 Blair-West, J. R., 823
 Blanchard, D. C., 775
 Blanchard, R. J., 775
 Blau, S., 127
 Bolger, G. T., 833
 Bossut, D. F., 1
 Bourguignon, J.-J., 85
 Boyeson, M. G., 497
 Bozarth, M. A., 485
 Brodish, A., 963
 Brosseau, L., 583
 Bruce, D. S., 705
 Burger, J., 7
 Burton, L. E., 617
 Butelman, E. R., 533
 Calcagnetti, D. J., 69
 Calcagnetti, R. L., 69
 Calvino, B., 731
 Calzà, L., 937
 Cancela, L., 335
 Canfield, D. R., 949
 Cao, W., 121
 Cappell, H., 373
 Carroll, M. E., 237
 Carvey, P. M., 291
 Casanova, M. F., 693
 Casas, M., 481, 753
 Chan, A. W. K., 363, 379
 Chance, W. T., 195
 Chandler, C. J., 285
 Chapouthier, G., 281
 Chesher, G. B., 861
 Clark, R., 537
 Clark, W. C., 397
 Cockroft, R., 461
 Coen, K. M., 351
 Coghill, R. C., 1
 Colas-Linhart, N., 885
 Collins, A. C., 171
 Commissaris, R. L., 451
 Connell, J. M., 469
 Cooper, S. J., 51
 Corrigan, W. A., 351
 Costall, B., 607, 955
 Cottrell, G. A., 307
 Coughlan, J., 955
 Crocker, A. D., 511
 Culbertson, J. W., 419
 Czyrak, A., 557
 Darling, N. K., 705
 Davis-Street, J. E., 677
 De Bellard, M. E., 133
 DeBold, J. F., 357
 de Caro, G., 823
 de Castro, J. M., 923
 de Luca, C., 933
 Denton, D. A., 823
 Desaubry, L., 85
 Dickson, C. T., 847
 Dilsaver, S. C., 523
 Dodd, R. H., 281
 Dohanich, G. P., 791
 Dokla, C. P. J., 151
 Domeney, A. M., 607, 955
 Doty, R. L., 699
 Dourish, C. T., 51
 Dunlap, W. P., 791
 Dwivedi, C., 767
 Eisenberg, M. S., 865
 Eison, A. S., 251
 Ekman, R., 165
 Ellison, G., 489
 English, M. J. M., 157
 Epstein, L. H., 671
 Erwin, V. G., 469
 Eterović, V. A., 255
 Evans, E. B., 631
 Evans, S. M., 971
 Fahey, M. A., 949
 Falk, J. L., 187, 419
 Fanselow, M. S., 69
 Fantino, M., 885
 Fassos, F. F., 219

- Feeney, D. M., 497
 Feenstra, M., 903
 Ferchmin, P. A., 255
 Fernandez-Briera, A., 75
 Fernández-Guasti, A., 263
 Fernstrom, M. H., 671
 Ferré, S., 481, 753
 Ferrer, A. C., 127
 Fico, T. A., 93
 File, S. E., 317
 Fischer, J. E., 195
 Fitten, L. J., 553
 Flemmer, D. D., 523
 Foley-Nelson, T., 195
 Fontana, D. J., 451
 Forster, M. J., 747
 Francès, H., 841
 Frank, C., 999
 Frank, R. A., 743
 Franklin, K. B. J., 157
 Freed, W. J., 693
 Frenk, H., 1
 Froehlich, J. C., 385
 Fudala, P. J., 89
 Fujiwara, H., 391

 Gadek, M. A., 503
 Gallo, M., 543
 George, F. R., 245
 Gerrard, P. A., 955
 Gessa, G. L., 601
 Giagnoni, G., 137
 Giardino, L., 937
 Gilmore, D. P., 571
 Giorgi, O., 877
 Glennon, R. A., 517
 Glowa, J. R., 803
 Gomá, M., 481
 Granier, M., 127, 133
 Grilly, D. M., 269
 Grogan, T. W., 269
 Groppetti, A., 137
 Grupp, L. A., 493
 Gudehithlu, K. P., 767
 Guix, T., 481, 753
 Güngör, M., 47, 829

 Haertzen, C. A., 397
 Hanna, J. A., 553
 Haraguchi, M., 259
 Hardwick, W. C., 797
 Harper, A. E., 911
 Harrell, L. E., 21
 Harts, J., 385
 Hatake, K., 437
 Hellevuo, K., 721
 Herberg, L. J., 815
 Hishida, S., 437
 Hoffman, A. J., 211
 Hughes, R. A., 567
 Hunt, T., 373
 Hunter, R. E., 791
 Huston, J. P., 989
 Hutchings, D. E., 93

 Ijiri, I., 437
 Irby, D., 739
 Itoh, T., 391
 Iwai, A., 727
 Iwamoto, E. T., 89

 Jackson, D. M., 861

 Jacob, R. G., 671
 Jaffe, K., 127, 133
 James, H., 617
 Janal, M. N., 397
 Jané, F., 481, 753
 Jeans, M. E., 157
 Jeffreys, R. D., 803
 Jias, L. M., 489
 Johanson, C. E., 971
 Johnson, M. P., 211
 Johnston, H. M., 571
 Johnston, J. L., 677
 Jones, B. C., 469

 Kamei, J., 473
 Kamien, J. B., 117, 949
 Kanarek, R. B., 301, 665
 Kao, L. C., 291
 Kasuya, Y., 473
 Kawai, T., 413
 Keller, E., 335
 Kellstein, D. E., 1
 Kelly, M. E., 607, 955
 Khidichian, F., 841
 Klawans, H. L., 291
 Kleven, M. S., 637
 Knott, V. J., 341
 Koob, G. F., 889
 Korpi, E. R., 721
 Koyuncuoglu, H., 47, 829
 Kragh, R., 237
 Kumor, K. M., 397
 Kunko, P. M., 871

 Lac, S. T., 237
 Lagarde, D., 713
 Lal, H., 747
 Landrum, R. E., 477
 Landrum, T. A., 477
 Lang, A., 855
 Langan, M. C., 363, 379
 Lau, C. E., 187, 419
 Laurent, J., 713
 Lemaire, G. A., 245, 443
 Leong, F. W., 363, 379
 Li, C., 699
 Li, T.-K., 385
 Lin, D. H., 291
 Lin, W., 739
 Lisciotto, C. A., 357
 Ljungberg, T., 111
 Llorens, J., 1003
 Logan, L. G., 121
 Louisot, P., 75
 Lumeng, L., 385

 McBurnie, M. I., 823
 McDaniel, K. L., 429
 McKearney, J. W., 181
 McMillan, D. E., 797
 McMillen, B. A., 465

 Madras, B. K., 949
 Maher, T. J., 865
 Maj, J., 557
 Malarkey, W., 767
 Marczynski, T. J., 503
 Margraf, R. R., 251
 Marks-Kaufman, R., 301, 665
 Marsland, A. L., 41
 Martin, R. J., 225
 Martin, W. R., 347, 651

 Mason, S. E., 785
 Massi, M., 823
 Massi, P., 137
 Massotti, M., 933
 Masukawa, Y., 413
 Mathis, C. A., 211
 Mayer, D. J., 1
 Mehrabani, P. A., 99
 Meisch, R. A., 245, 443
 Melchers, B. P. C., 321
 Melchior, J.-C., 885
 Mele, L., 933
 Melis, M. R., 601
 Meliska, C. J., 477
 Menon, M. K., 553
 Messiha, F. S., 29
 Meyer, M. E., 307
 Meyer, S., 775
 Miczek, K. A., 357
 Milhaud, C., 713
 Milius, R. A., 949
 Miñano, F. J., 465
 Mintz, M., 815
 Misenheimer, B., 517
 Misslin, R., 85
 Mitchell, J. B., 367, 643
 Miyate, H., 143, 391
 Mogilnicka, E., 557
 Molina, V. A., 335
 Monier, C., 841
 Moody, C. A., 743
 Morelis, R., 75
 Mos, J., 781
 Mucha, R. F., 219
 Mueller, K., 871
 Mundy, W. R., 429
 Murai, S., 391
 Murray, A. M., 105
 Murúa, V. S., 335
 Museo, E., 735
 Myers, R. D., 465

 Nagahama, H., 391
 Naylor, R. J., 607, 955
 Nelson, J. L., 195
 Neumeyer, J. L., 949
 Nichols, D. E., 211
 Nierenberg, J., 405
 Nilekani, S. P., 705

 Odio, M., 963
 Oeltgen, P. R., 705
 Ogawa, M., 473
 Oishi, R., 897
 Okada, K., 897
 Olivier, B., 781
 Onaivi, E. S., 955
 O'Neill, S. K., 833
 Ouchi, H., 437
 Owens, S. M., 797
 Ozawa, Y., 727

 Papadakis, E., 451
 Parenti, M., 137
 Parker, L. A., 583
 Parker, S. C., 151
 Parolaro, D., 137
 Parsons, D. S., 21
 Patrini, G., 137
 Paule, M. G., 759
 Pauly, J. R., 171
 Payne, A. P., 571

 Peagler, A., 21
 Penetrante, M. L., 363, 379
 Perkins, K. A., 671
 Perlanski, E., 493
 Perrignon, A., 861
 Perryman, K. M., 553
 Peters, D. A. V., 943
 Peters, G., 61
 Philippens, H. C. H. M., 561
 Phillips, A. G., 685
 Piazza, P. V., 937
 Picker, Z., 327
 Poling, A., 537
 Poltorak, M., 693
 Pomerantz, S. M., 659
 Poulos, C. X., 373
 Pourmaghash, S., 803
 Prat, G., 481, 753
 Pruitt, T. A., 347
 Puerto, A., 543
 Pugsley, T. A., 589

 Raffalli-Sebille, M.-J., 281
 Rebec, G. V., 55
 Repa, J. J., 911
 Ribbi-Jaffe, A., 127
 Rigaud, D., 885
 Riley, A. L., 803
 Risser, J. M., 699
 Roane, D. S., 225
 Robinson, N. L., 617
 Roldán-Roldán, G., 263
 Rose, I. C., 815
 Rosenwasser, A. M., 35
 Rozen, R., 885
 Russell, R. W., 511
 Rönnbäck, L., 15

 Saeki, K., 897
 Sağduyu, H., 47, 829
 Sagratella, S., 999
 Saha, J. K., 949
 Saito, H., 231
 Saito, Y., 391
 Sakaki, N., 437
 Saldívar, A., 263
 Salmon, P., 41
 Samson, H. H., 259
 Satter, B. C., 767
 Schanley, D. L., 363, 379
 Schechter, M. D., 527
 Schlinger, H., 537
 Schreiber, J. F., 889
 Schulze, G. E., 759
 Schwarting, R. K. W., 989
 Schwarz, R. D., 589
 Scotti de Carolis, A., 999
 Seale, T. W., 121
 Seeland, K. J., 705
 Seiden, L. S., 995
 Sexton, J. E., 671
 Sharma, H. M., 767
 Shaw, C., 493
 Shulgin, A. T., 211
 Singer, G., 739
 Singh, R., 291
 Siwanowicz, J., 557
 Slangen, J. L., 781
 Sloan, J. W., 347, 651
 Sobrian, S. K., 617
 Soosaar, A., 855

Spealman, R. D., 949
Spencer, C. J., 589
Stähle, L., 201
Stancampiano, R., 601
Stanford, S. C., 41
Starmer, G. A., 861
Starr, B. S., 285
Starr, M. S., 285
Steger, R. W., 577
Steiner, H., 989
Stewart, J., 367, 643
Stiller, R. L., 671
Stokes, D. L., 617
Stroet, J., 903
Suh, H. H., 807
Suñol, C., 1003
Suzuki, T., 413
Swiergiel, A. H., 61
Szmydynger-Chodobska, J.,
823
Tablante, A., 127, 133
Tang, M., 187, 419
Taniguchi, T., 437
Tarjan, E., 823
Tasker, R. A. R., 157
Tejwani, G. A., 767
Terry, P., 41
Tews, J. K., 911
Thal, L. J., 151
Tilson, H. A., 429
Tolliver, G. A., 259
Tomkins, D. M., 607, 955
Toth, P., 493
Toubas, P. L., 121
Tseng, L. F., 807
Tuominen, K., 721
Turner, L. M., 617
Tusell, J. M., 1003
Tyers, M. B., 955
Ullman, E. A., 171
Ungerstedt, U., 201
Urbanicic, M., 503
Vanderwolf, C. H., 847
van Haaren, F., 903
Van Hartesveldt, C., 307
van Helden, H. P. M., 321
van Hest, A., 903
Vanwersch, R., 561
Vasar, E., 855
Vécsei, L., 165
Venault, P., 281
Vigorito, M., 187
Virus, R. M., 637
Vogel, E., 85
Volosin, M., 335
Waddington, J. L., 105
Wala, E. P., 347, 651
Walker, M. J. K., 219
Ward, L., 785
Weinger, M. B., 889
Weisinger, R. S., 823
Weiss, S. M., 775
Wellman, P. J., 457, 461
Wenger, G. R., 595, 631
Wermuth, C. G., 85
Wessinger, W. D., 797
Widerlöv, E., 165
Wilks, L. J., 317
Willard, M., 85
Wilson, C. A., 571
Wise, R. A., 735
Wolgin, D. L., 273
Wolthuis, O. L., 561
Woolverton, W. L., 117,
637
Wright, D. W., 595
Wright, R. N., 251
Yamamoto, M., 727
Yanaura, S., 413
Ybema, C. E., 781
Yocca, F. D., 251
Young, S. N., 157
Zabala, N. A., 127, 133
Zacny, J. P., 637, 971
Zhang, T. J., 291